

LIFE SAVING DRUGS PROGRAM EXPERT PANEL

18th MEETING: 28 June 2024

AGENDA

1. Standing business

- 1.1 Welcome, apologies and Conflicts of Interest
- 1.2 Update on actions from previous meetings
- 1.3 Correspondence
- 1.4 Report from the Secretariat

2. 24 month review of existing LSDP medicines

- 2.1 Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease

3. Other business

- 3.1 HTA Policy and Methods Review
- 3.2 Expansion of the newborn bloodspot screening program: Implications for the LSDP

Note: There are no applications for new listings being discussed at this meeting.